Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





TB-Related Articles										Related Pages
										Journal Articles Published by Division of TB Elimination (DTBE) Authors
2016 DTBE Publications
Auld AF, Agizew T, Pals S, Finlay A, Ndwapi N, Boyd R, Alexander H, Mathoma A, Basotli J, Gwebe-Nyirenda S, Shepherd J, Ellerbrock TV, Date A. Implementation of a pragmatic, stepped-wedge cluster randomized trial to evaluate impact of Botswana’s Xpert MTB/RIF diagnostic algorithm on TB diagnostic sensitivity and early antiretroviral therapy mortality.external icon BMC Infect Dis. 2016 Oct 26;16(1):606. PMID: 27782821.
Auld SC, Lee SH, Click ES, Miramontes R, Day CL, Gandhi NR, Heilig CM. IFN-γ Release Assay Result Is Associated with Disease Site and Death in Active Tuberculosis. Ann Am Thorac Soc.external icon 2016 Dec;13(12):2151-2158. PMID: 27580246.
Baker BJ, Winston CA, Liu Y, France AM, Cain KP. Abrupt Decline in Tuberculosis among Foreign-Born Persons in the United States.external icon PLoS One. 2016 Feb 10;11(2):e0147353. doi: 10.1371/journal.pone.0147353. eCollection 2016. PMID: 26863004.Year202120202019201820172016201520142013*Bemis K, Thornton A, Rodriguez-Lainz A, Lowenthal P, Escobedo M, Sosa LE, Tibbs A, Sharnprapai S, Moser KS, Cochran J, Lobato MN.*Civil Surgeon Tuberculosis Evaluations for Foreign-Born Persons Seeking Permanent U.S. Residence. J Immigr Minor Health.external icon 2016 Apr;18(2):301-7. doi: 10.1007/s10903-015-0169-1. PMID: 25672993.
Brostrom R, Wasserman G, Hayes D. Insights in Public Health: Eliminating Tuberculosis in Hawai’i: Yesterday, Today, and Tomorrow.external icon Hawaii J Med Public Health. 2016 Apr;75(4):117-20. PMID: 27099808.
Castro KG, Marks SM, Chen MP, Hill AN, Becerra JE, Miramontes R, Winston CA, Navin TR, Pratt RH, Young KH, LoBue PA. Estimating tuberculosis cases and their economic costs averted in the United States over the past two decades.external icon Int J Tuberc Lung Dis. 2016 Jul;20(7):926-33. doi: 10.5588/ijtld.15.1001. PMID: 27287646.
CDC (Buss BF, Keyser-Metobo A, Rother J, Holtz, L, Gall K, Jereb J, Murphy CN, Iwen PC, Robbe-Austerman S, Holcomb, MA, Infield P) Possible Airborne Person-to-Person Transmission of *Mycobacterium bovis* — Nebraska 2014–2015. MMWR 2016 March 4; 65(8):197–201.
CDC (Salinas JL, Mindra G, Haddad MB, Pratt R, Price SF, Langer AJ) Leveling of Tuberculosis Incidence — United States, 2013–2015. MMWR 2016 March 25; 65(11);273-78.
CDC (Weinberg MP, Cherry C, Lipnitz J, Nienstadt L, King-Todd A, Haddad MB, Russell M, Wong D, Davidson P, McFadden J, Miller C.) Tuberculosis Among Temporary Visa Holders Working in the Tourism Industry – United States, 2012-2014. MMWR 2016 March 25; 65(11);279-81.
CDC (Young KH, Ehman M, Reves R, Peterson Maddox BL, Khan A, Chorba TL, Jereb J) Tuberculosis contact investigations—United States, 2003–2012pdf icon. MMWR 2016 Jan 1;64(50-51):1369-74.
Chorba T, Breedlove B. Depictions of Heroism in Battle and Anguish from Tuberculosis.
Emerg Infect Dis.external icon 2016 Mar;22(3):573-4. doi: 10.3201/eid2203.AC2203. PMID: 27326438.
Clark CD, Langkjaer S, Chinikamwala S, Joseph H, Semaan S, Clement J, Marshall R, Pevzner E, Truman BI, Kroeger K. Providers’ Perspectives on Program Collaboration and Service Integration for Persons Who Use Drugs.external icon J Behav Health Serv Res. 2016 Mar 4. doi: 10.1007/s11414-016-9506-y. [Epub ahead of print]. PMID: 26943642.
Farhat MR, Sultana R, Iartchouk O, Bozeman S, Galagan J, Sisk P, Stolte C, Nebenzahl-Guimaraes H, Jacobson K, Sloutsky A, Kaur D, Posey J, Kreiswirth BN, Kurepina N, Rigouts L, Streicher EM, Victor TC, Warren RM, van Soolingen D, Murray M. Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic Value. Am J Respir Crit Care Med.external icon 2016 Feb 24. doi: 10.1164/rccm.201510-2091OC. [Epub ahead of print]. PMID: 26910495.
Fletcher R, Jones JD, Shah NS. Treatment of Active Tuberculosis in Chicago, 2008-2011: The Role of Public Health Departments.external icon PLoS One. 2016 Oct 12;11(10):e0164162. doi: 10.1371/journal.pone.0164162. PMID: 27732650.
Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang’wa B, du Cros P. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. Int J Tuberc Lung Dis.external icon 2016 Mar;20(3):290-4. doi: 10.5588/ijtld.15.0490. PMID: 27046707.
Garzan A, Willby MJ, Green KD, Gajadeera CS, Hou C, Tsodikov OV, Posey JE, Garneau-Tsodikova S. Sulfonamide-Based Inhibitors of Aminoglycoside Acetyltransferase Eis Abolish Resistance to Kanamycin in Mycobacterium tuberculosis.external icon J Med Chem. 2016 Dec 8;59(23):10619-10628. PMID: 27933949.
Garzan A, Willby MJ, Green KD, Tsodikov OV, Posey JE, Garneau-Tsodikova S. Discovery and Optimization of Two Eis Inhibitor Families as Kanamycin Adjuvants against Drug-Resistant M. tuberculosis. ACS Med Chem Lett.external icon 2016 Sep 15;7(12):1219-1221. eCollection 2016. PMID: 27994767.
Grinsdale JA, Islam S, Tran OC, Ho CS, Kawamura LM, Higashi JM. Interferon-Gamma Release Assays and Pediatric Public Health Tuberculosis Screening: The San Francisco Program Experience 2005 to 2008.external icon J Pediatric Infect Dis Soc. 2016 Jun;5(2):122-30. doi: 10.1093/jpids/piu119. Epub 2014 Dec 15. PMID: 27199468.
Heidebrecht CL, Podewils LJ, Pym AS, Cohen T, Mthiyane T, Wilson D. Assessing the utility of Xpert(®) MTB/RIF as a screening tool for patients admitted to medical wards in South Africa.external icon Sci Rep. 2016 Jan 20;6:19391. doi: 10.1038/srep19391. PMID: 26786396.
Heidebrecht CL, Podewils LJ, Pym A, Mthiyane T, Cohen T. Assessing Local Risk of Rifampicin-Resistant Tuberculosis in KwaZulu-Natal, South Africa Using Lot Quality Assurance Sampling. PLoS One.external icon 2016 Apr 6;11(4):e0153143. doi: 10.1371/journal.pone.0153143. eCollection 2016. PMID: 27050561.
Jayakumar A, Savic RM, Everett CK, Benator D, Alland D, Heilig CM, Weiner M, Friedrich SO, Martinson NA, Kerrigan A, Zamudio C, Goldberg SV, Whitworth WC, Davis JL, Nahid P. Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure.external icon J Clin Microbiol. 2016 Dec;54(12):3028-3033. doi:
10.1128/JCM.01313-16external icon. Epub 2016 Oct 12. PMID: 27733634.
Jereb JA. Interpreting False Positive Tuberculosis Tests in Occupational Screening: The Fault of the Test, the Testing Schedule, or Both?external icon Ann Am Thorac Soc. 2016 Jul;13(7):1189-90. doi: 10.1513/AnnalsATS.201604-252LE. PMID: 27388411.
Jewett A, Bell T, Cohen NJ, Buckley K, Leino EV, Even S, Beavers S, Brown C, Marano N. US college and university student health screening requirements for tuberculosis and vaccine-preventable diseases, 2012. J Am Coll Health.external icon 2016 Jul;64(5):409-15. doi: 10.1080/07448481.2015.1117465. Epub 2016 Jan 5. PMID: 26730492.
Johnson MG, Stout JE, Benator DA, Whitworth WC, Holland DP. Medium matters: modeling the impact of solid medium performance on tuberculosis trial sample size requirements**.**Int J Tuberc Lung Dis. 2016 May; 20(5):600-4. doi: 10.5588/ijtld.15.0570. PMID: 27084812.
Juarez-Reyes M, Gallivan M, Chyorny A, O’Keeffe L, Shah NS. Completion Rate and Side-Effect Profile of Three-Month Isoniazid and Rifapentine Treatment for Latent Tuberculosis Infection in an Urban County Jail.external icon Open Forum Infect Dis. 2016 Jan 6;3(1):ofv220. doi: 10.1093/ofid/ofv220. eCollection 2016 Jan. PMID: 26885547.
Kaniga K, Cirillo DM, Hoffner S, Ismail NA, Kaur D, Lounis N, Metchock B, Pfyffer GE, Venter A. A Multi-Laboratory, Multi-Country Study to Determine Bedaquiline Minimal Inhibitory Concentration Quality Control Ranges for Phenotypic Drug-Susceptibility Testing.external icon J Clin Microbiol. 2016 Sep 21; pii: JCM.01123-16. [Epub ahead of print] PMID: 27654337.
Kaniga K, Cirillo DM, Hoffner S, Ismail NA, Kaur D, Lounis N, Metchock B, Pfyffer GE, Venter A. A Multi-Laboratory, Multi-Country Study to Determine Minimal Inhibitory Concentration Quality Control Ranges for PhenotypicDrug-Susceptibility Testing of Selected First-Line Anti-TB Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine and Linezolid.external icon J Clin Microbiol. 2016 Sep 21; pii: JCM.01138-16. [Epub ahead of print]. PMID: 27654338.
Khan A. National Tuberculosis Prevention and Control Program Evaluation in the United States of America: From Concept to Practice. Austin Tuberc Res Treat. 2016;1(1):1001.
Kim L, Moonan PK, Heilig CM, Woodruff RS, Kammerer JS, Haddad MB. Factors associated with recurrent tuberculosis more than 12 months after treatment completion.external icon Int J Tuberc Lung Dis. 2016 Jan;20(1):49-56. doi: 10.5588/ijtld.15.0442. PMID: 26688528.
Lambert LA, Armstrong LR, Lobato MN, Ho C, France AM, Haddad MB. Tuberculosis in Jails and Prisons: United States, 2002-2013.external icon Am J Public Health. 2016 Sep 15:e1-e7 [Epub ahead of print]. PMID: 27631758.
Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O’Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.external icon Clin Infect Dis. 2016 Dec 8. pii: ciw694. [Epub ahead of print]. PMID: 27932390.
Luetkemeyer AF, Firnhaber C, Kendall MA, Wu X, Mazurek GH, Benator DA; Arduino R, Fernandez M, Guy E, Johnson P, Metchock B, Sattler F, Telzak E, Wang YF, Weiner M, Swindells S, Sanne IM, Havlir DV, Grinsztejn B, Alland D; AIDS Clinical Trials Group A5295 and Tuberculosis Trials Consortium Study 34 Teams. Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings. Clin Infect Dis.external icon 2016 May 1;62(9):1081-8. doi: 10.1093/cid/ciw035. Epub 2016 Feb 2. PMID: 26839383
Mangan JM, Tupasi TE, Garfin AM, Lofranco V, Orillaza-Chi R, Basilio R, Naval LC, Balane GI, Joson ES, Burt D, Lew WJ, Mantala M, Pancho S, Sarol JN, Golubkov A, Kurbatova EV. Multidrug-resistant tuberculosis patients lost to follow-up: self-reported readiness to restart treatment.external icon Int J Tuberc Lung Dis. 2016 Sep;20(9):1205-11. doi: 10.5588/ijtld.16.0029. PMID: 27510247.
Marks SM, Hirsch-Moverman Y, Salcedo K, Graviss EA, Oh P, Seaworth B, Flood J, Armstrong L, Armitige L, Mase S; TB Epidemiologic Studies Consortium. Characteristics and costs of multidrug-resistant tuberculosis in-patient care in the United States, 2005-2007. Int J Tuberc Lung Dis.external icon 2016 Apr;20(4):435-41. doi: 10.5588/ijtld.15.0575. PMID: 26970150.
*Mase SR, Jereb JA, Gonzalez D, Martin F, Daley CL, Fred D, Loeffler AM, Menon LR, Bamrah Morris S, Brostrom R, Chorba T, Peloquin CA.*Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands. Pediatr Infect Dis J.external icon 2016 Apr;35(4):414-21. doi: 10.1097/INF.0000000000001022. PMID: 26658531.
Mindra G, Wortham JM, Haddad MB, Salinas JL, Powell KM, Armstrong LR. Tuberculosis Among Incarcerated Hispanic Persons in the United States, 1993-2014.external icon J Immigr Minor Health. 2016 Nov 29. [Epub ahead of print]. PMID: 27900592.
Mitruka K, Volkmann T, Pratt RH, Kammerer JS. Disparities in Tuberculosis Treatment Completion by Incarceration Status, U.S., 1999-2011.external icon Am J Prev Med. 2016 Dec 21. pii: S0749-3797(16)30571-2. doi: 10.1016/j.amepre.2016.10.035. [Epub ahead of print]. PMID: 28012812.
Modi S, Cavanaugh JS, Shiraishi RW, Alexander HL, McCarthy KD, Burmen B, Muttai H, Heilig CM, Nakashima AK, Cain KP. Performance of Clinical Screening Algorithms for Tuberculosis Intensified Case Finding among People Living with HIV in Western Kenya.external icon PLoS One. 2016 Dec 9;11(12):e0167685. doi: 10.1371/journal.pone.0167685. PMID: 27936146.
Moro RN, Borisov A, Saukkonen J, Khan A, Sterling TR, Villarino ME, Scott NA, Shang N, Kerrigan A, Goldberg SV. Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada. Clin Infect Dis.external icon 2016 Jun 1;62(11):1390-400. doi: 10.1093/cid/ciw126. Epub 2016 Mar 6. PMID: 26951571.
Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O’Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.external icon Clin Infect Dis. 2016 Oct 1;63(7):853-67. doi: 10.1093/cid/ciw566. PMID: 27621353.
Nandakumar S, Kannanganat S, Dobos KM, Lucas M, Spencer JS, Amara RR, Plikaytis BB, Posey JE, Sable SB. Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis.external icon Sci Rep.external icon 2016 May 13;6:25837. doi: 10.1038/srep25837. PMID: 27173443.
Nnadi CD, Anderson LF, Armstrong LR, Stagg HR, Pedrazzoli D, Pratt R, Heilig CM, Abubakar I, Moonan PK. Mind the gap: TB trends in the USA and the UK, 2000-2011. Thorax.external icon 2016 Apr;71(4):356-63. doi: 10.1136/thoraxjnl-2015-207915. Epub 2016 Feb 23. PMID: 26907187.
Nandi P, Worrell MC, Andrews T, Sales RM, McMichael J, Hampton KH, Goswami ND. Engaging homeless service providers in educational efforts during a tuberculosis outbreak in Atlanta. J Ga Public Health Assoc 2016; 6(2):279-82. https://doi.org/10.21633/jgpha.6.2s14external icon.
Olea-Popelka F, Muwonge A, Perera A, Dean AS, Mumford E, Erlacher-Vindel E, Forcella S, Silk BJ, Ditiu L, El Idrissi A, Raviglione M, Cosivi O, LoBue P, Fujiwara PI. Zoonotic tuberculosis in human beings caused by Mycobacterium bovis-a call for action.external icon Lancet Infect Dis. 2016 Sep 30; pii: S1473-3099(16)30139-6. doi: 10.1016/S1473-3099(16)30139-6. Review.[Epub ahead of print]. PMID: 27697390.
Pathak RR, Mishra BK, Moonan PK, Nair SA, Kumar AM, Gandhi MP, Mannan S, Ghosh S. Can Intensified Tuberculosis Case Finding Efforts at Nutrition Rehabilitation Centers Lead to Pediatric Case Detection in Bihar, India?external icon J Tuberc Res. 2016 Mar 30;4(1):46-54. PMID: 27066518.
Peloquin CA, Dorman SE, Vernon A, Battista Migliori G, Nahid P. Reply to Alffenaar et al.external icon Clin Infect Dis. 2016 Oct 26. pii: ciw679. No abstract available. [Epub ahead of print]. PMID: 27789610
Podewils LJ, Bronner Murrison L, Bristow C, Bantubani N, Mametja LD. The other side of surveillance: Monitoring, application, and integration of tuberculosis data to guide and evaluate programme activities in South Africa. S Afr Med J.external icon 2016 Mar 10;106(4):394-8. doi: 10.7196/SAMJ.2016.v106i4.10207. PMID: 27032857.
Scott C, Cavanaugh JS, Pratt R, Silk BJ, LoBue P, Moonan PK. Human tuberculosis caused by Mycobacterium bovis in the United States, 2006-2013.external icon Clin Infect Dis. 2016 Jun 13. pii: ciw371. doi: 10.1093/cid/ciw371. [Epub ahead of print.] PMID: 27298329
Shah NS, Grace Lin SY, Barry PM, Cheng YN, Schecter G, Desmond E. Clinical Impact on Tuberculosis Treatment Outcomes of Discordance Between Molecular and Growth-Based Assays for Rifampin Resistance, California 2003-2013.external icon Open Forum Infect Dis. 2016 Aug 24;3(3):ofw150. PMID: 27704008.
Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, Chen MP, Benator DA, Gordin F, Benson CA, Chaisson RE, Villarino ME; Tuberculosis Trials Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259). Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.external icon AIDS. 2016 Jun 19;30(10):1607-15.
doi: 10.1097/QAD.0000000000001098. PMID:27243774.
Tupasi T, Garfin AM, Kurbatova EV, Mangan JM, Orillaza-Chi R, Naval LC, Balane GI, Basilio R, Golubkov A, Joson ES, Lew WJ, Lofranco V, Mantala M, Pancho S, Sarol JN Jr. Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012-2014. Emerg Infect Dis.external icon 2016 Mar;22(3). doi: 10.3201/eid2203.151788. PMID: 26889786.
Teeter LD, Vempaty P, Nguyen DT, Tapia J, Sharnprapai S, Ghosh S, Kammerer JS, Miramontes R, Cronin WA, Graviss EA; Tuberculosis Epidemiologic Studies Consortium. Validation of genotype cluster investigations for Mycobacterium tuberculosis: application results for 44 clusters from four heterogeneous United States jurisdictions.external icon BMC Infect Dis. 2016 Oct 21;16(1):594. PMID: 27769182.
Trinidad RM, Brostrom R, Morello MI, Montgomery D, Thein CC, Gajitos ML, Heetderks A, Chorba T. Tuberculosis screening at a diabetes clinic in the Republic of the Marshall Islandsexternal icon. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 2016 Dec; 5;4-7. http://dx.doi.org/10.1016/j.jctube.2016.10.001external icon.
Tyrrell F, Stafford C, Yakrus M, Youngblood M, Hill A, Johnston S. Trends in Testing for Mycobacterium tuberculosis Complex From US Public Health Laboratories, 2009-2013. Public Health Rep.external icon 2017 Jan/Feb;132(1):56-64. doi: 10.1177/0033354916679989. Epub 2016 Dec 12. PMID: 28005481.
Velásquez GE, Cegielski JP, Murray MB, Yagui MJ, Asencios LL, Bayona JN, Bonilla CA, Jave HO, Yale G, Suárez CZ, Sanchez E, Rojas C, Atwood SS, Contreras CC, Cruz JS, Shin SS. Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study.external icon BMC Infect Dis. 2016 Feb 1;16(1):45. doi: 10.1186/s12879-016-1375-8. PMID: 26831140.
Volkmann T, Okelloh D, Agaya J, Cain K, Ooko B, Malika T, Burton D. Pilot implementation of a contact tracing intervention for tuberculosis case detection in Kisumu County, Kenya. Public Health Action. 2016 Dec 21:6(4):217-219. doi: 10.5588/pha.16.0032.
Volkmann T, Moonan PK, Miramontes R, Oeltmann JE. Excess Alcohol Use and Death among Tuberculosis Patients in the United States, 1997-2012.external icon J Tuberc Res. 2016 Mar;4(1):18-22. doi: 10.4236/jtr.2016.41003. PMID: 27054144.
Webb Mazinyo E, Kim L, Masuku S, Lancaster JL, Odendaal R, Uys M, Podewils LJ, Van der Walt ML. Adherence to Concurrent Tuberculosis Treatment and Antiretroviral Treatment among Co-Infected Persons in South Africa, 2008-2010.external icon PLoS One. 2016 Jul 21;11(7):e0159317. doi: 10.1371/journal.pone.0159317. eCollection 2016. PMID: 27442440.
Willby MJ, Green KD, Gajadeera CS, Hou C, Tsodikov OV, Posey JE, Garneau-Tsodikova S. Potent Inhibitors of Acetyltransferase Eis Overcome Kanamycin Resistance in Mycobacterium tuberculosis. ACS Chem Biol.external icon 2016 Jun 17;11(6):1639-46. doi: 10.1021/acschembio.6b00110. Epub 2016 Apr 7. PMID: 27010218.
Yakrus, MA, Driscoll J, McAlister A, Sikes A, Hartline D, Metchock B, Starks AM. Molecular and Growth-Based Drug Susceptibility Testing of Mycobacterium tuberculosis Complex for Ethambutol Resistance in the United States. Tuberc Res Treat.external icon 2016;2016:3404860. doi: 10.1155/2016/3404860. Epub 2016 Jun 8. PMID: 27375902.
Yuen CM, Kammerer JS, Marks K, Navin TR, France AM. Recent Transmission of Tuberculosis – United States, 2011-2014.external icon PLoS One. 2016 Apr 15;11(4):e0153728. doi: 10.1371/journal.pone.0153728. eCollection 2016. PMID: 27082644.
Zetola NM, Modongo C, Moonan PK, Click E, Oeltmann JE, Shepherd J, Finlay A. Protocol for a population-based molecular epidemiology study of tuberculosis transmission in a high HIV-burden setting: the Botswana Kopanyo study.external icon BMJ Open. 2016 May 9;6(5):e010046. doi: 10.1136/bmjopen-2015-010046. PMID: 27160840.

*Last updated February 10, 2017*
							
					
						Page last reviewed:  October 21, 2016					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosis
Basic TB Factsplus icon
How TB Spreads
Latent TB Infection and TB Disease
Signs & Symptoms
TB Risk Factors
Exposure to TB
TB Prevention
Vaccines
TB & HIV Coinfection
TB and Diabetes
TB Terms
Personal Storiesplus icon
Stories by Topic
Archived Stories
Testing & Diagnosisplus icon
Who Should be Tested
Testing for TB Infection
Testing in BCG-Vaccinated Persons
TB Screening and Testing of Health Care Personnel
Testing During Pregnancy
Diagnosing latent TB infection and TB disease
Treatmentplus icon
Deciding When to Treat Latent TB Infection
Treatment Regimens for Latent TB Infection (LTBI)
Treatment for TB Disease
Adverse Events
TB Treatment of Persons Living with HIV
TB Treatment and Pregnancy
TB Treatment for Children
Drug-Resistant TB
Researchplus icon
TB Epidemiologic Studies Consortiumplus icon
Research Projects
Publications
TB Trials Consortiumplus icon
Study Descriptions
Background
Behavioral & Social Science Research
Health Care Settingsplus icon
TB Infection Control in Health Care Settings
Resources for TB Screening and Testing of Health Care Personnelplus icon
Frequently Asked Questions
TB in Specific Populationsplus icon
Health Disparities
Asian Persons
Black or African American Persons
Hispanic or Latino Persons
Children
Pregnancy
Correctional Facilities
People Experiencing Homelessness
International Travelers
Laboratory Informationplus icon
Drug Susceptibility Testing
False-Positive Investigation Toolkit
Interim Laboratory Biosafety Guidance for XDR *Mycobacterium* tuberculosis strains
Model Performance Evaluation Program (MPEP)
Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus icon
Executive Summary
Introduction
Background on Tests for Molecular Detection of DR
General Considerations and Principles for a Molecular DR Testing Service
Possible Scenarios and Scope of Testing for a Molecular DR Testing Service
Research Needs
General Recommendations of the Expert Panel
Communication Plan for the Report
Recommendations
References
Panel Members and CDC Participants
Appendix 1
Appendix 2
Appendix 3
The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus icon
General Considerations
General Recommendations of the Expert Panel
Recommendations to ACET, CDC, DTBE
Data & Statisticsplus icon
TB Incidence in the United States
Reported TB in the US, 2019 Surveillance Report
Trends in Tuberculosis 2019
Tuberculosis in the United States, 2019 (Slide Set)
Archived Surveillance Reports and Slide Sets
2019 State and City Report
Archived State and City Reports
Professional Resources & Toolsplus icon
Tools for Healthcare Providersplus icon
Interactive Core Curriculum on Tuberculosis: What the Clinician Should Know
Resources for TB Programsplus icon
Notice of Funding Opportunity (NOFO)
Program Evaluation
TB Centers of Excellence
TB Community Engagement Network
Publications & Productsplus icon
Patient and Public Materials
Fact Sheetsplus icon
General
Data & Statistics
Drug-Resistant TB
Infection Control & Prevention
TB in Specific Populations
Treatment
Testing & Diagnosis
Vaccines & Immunizations
Guidelinesplus icon
Control & Elimination
Drug-Resistant TB
Infection Control & Prevention
Laboratory & Genotyping
TB & HIV
TB in Specific Populations
Testing & Diagnosis
Treatment
Vaccines & Immunizations
Archived TB Guidelines
Guides & Toolkitsplus icon
Aggregate Reports
CDC TB Surveillance Training
Core Curriculum
Effective TB Interviewing for Contact Investigation
Ethnographic Guides
False-Positive Investigation Toolkit
Forging Partnerships to Eliminate TB
Guide to Application of Genotyping
LTBI: A Guide for Primary Health Care Providers
Mantoux Tuberculin Skin Testing Products
Report of Verified Case of Tuberculosis (RVCT)
Self-Study Modules
TB Contact Investigation Interviewing Skills Course
TB eDOT Toolkit
Understanding the TB Cohort Review Process
Newslettersplus icon
TB Notes, No. 1, 2021
TB Notes, No. 4, 2020
TB Notes, No. 3, 2020
TB Notes, No. 2, 2020
TB Notes, No. 1, 2020
TB Notes, No. 4, 2019
TB Notes, No. 3, 2019
TB Notes, No. 2, 2019
TB Notes, No. 1, 2019
TB Notes, No. 6, 2018
TB Notes, No. 5, 2018
TB Notes, No. 4, 2018
TB Notes, No. 3, 2018
TB Notes, No. 2, 2018
TB Notes, No. 1, 2018
TB Notes, No. 5, 2017
TB Notes, No. 4, 2017
TB Notes, No. 3, 2017
TB Notes, No. 2, 2017
TB Notes, No. 1, 2017
TB Notes, No. 5, 2016
TB Notes, No. 4, 2016
TB Notes, No. 3, 2016
TB Notes, No. 2, 2016
TB Notes, No. 1, 2016
Pamphlets, Brochures, Bookletsplus icon
Questions and Answers
Patient Education Series
Tuberculosis – Get the Facts
Tuberculosis – The Connection between TB and HIV
12-Dose Regimen for Latent TB Infection-Patient Education Brochure
Postersplus icon
Mantoux Tuberculin Skin Test Wall Chart
World TB Day
Think TB
Stop TB
Take on TB
Reports & Articlesplus icon
DTBE Authored Journal Articles
Tuberculosis Laboratory Aggregate Reports
Slide Setsplus icon
Introduction to Tuberculosis
Epidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016
Self-Study Modules on Tuberculosis, 1-5 Slide Sets
The Tuberculosis (TB) in Correctional Settingsplus icon
Facilitator Guide
Introduction to TB Genotyping
Epidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017
Prevention and Control of Tuberculosis in Correctional and Detention Facilities
Guidelines for Preventing the Transmission of M. TB in Health care Settings
Investigation of Contacts of Persons with Infectious TB
Epidemiology of Pediatric Tuberculosis in the United States
Targeted Tuberculosis Testing and Treatment of Latent Tuberculosis Infection
Electronic Tools & Resources
Web-Based Courses & Webinarsplus icon
TB 101 for Health Care Workersplus icon
TB 101
Interactive Core Curriculum
Content Syndication
Infographicsplus icon
Social Media Graphics
Customizable Take on TB Infographic with Instructions
Events
World TB Dayplus icon
Resources
U.S. TB Championsplus icon
2021 CDC U.S. TB Elimination Champions
2020 CDC U.S. TB Elimination Champions
2019 CDC U.S. TB Elimination Champions
2018 CDC U.S. TB Elimination Champions
2017 CDC U.S. TB Elimination Champions
2016 CDC U.S. TB Elimination Champions
News & Events
History
Featuresplus icon
TB Risk Factors
Treating Latent TB Infection with Short-Course Regimens
World Tuberculosis (TB) Day 2021
World Tuberculosis (TB) Day 2020
Linksplus icon
State TB Control Offices
About Usplus icon
Mission Statement and Activitiesplus icon
DTBE Strategic Plan
National TB Program Objectives
Organization Chart
Advisory Groupsplus icon
Federal TB Task Force


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue